Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much.

Literature DB >> 28359029

Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much.

Robert Peter Gale¹, Gerhard Opelz².

Abstract

Entities: Disease

Mesh：

Year: 2017 PMID： 28359029 DOI： 10.1016/j.leukres.2017.03.003

Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

1. E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

Authors: Simone Claudiani; Jane F Apperley; Robert Peter Gale; Richard Clark; Richard Szydlo; Simona Deplano; Renuka Palanicawandar; Jamshid Khorashad; Letizia Foroni; Dragana Milojkovic
Journal: Haematologica Date: 2017-05-11 Impact factor: 9.941

Review 2. A Tumor Profile in Primary Immune Deficiencies Challenges the Cancer Immune Surveillance Concept.

Authors: Daniel Satgé
Journal: Front Immunol Date: 2018-05-24 Impact factor: 7.561

Review 3. Chronic myeloid leukemia stem cells.

Authors: Mohammad Houshmand; Giorgia Simonetti; Paola Circosta; Valentina Gaidano; Alessandro Cignetti; Giovanni Martinelli; Giuseppe Saglio; Robert Peter Gale
Journal: Leukemia Date: 2019-05-24 Impact factor: 11.528

4. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology.

Authors: Vlad Moisoiu; Patric Teodorescu; Lorand Parajdi; Sergiu Pasca; Mihnea Zdrenghea; Delia Dima; Radu Precup; Ciprian Tomuleasa; Simona Soverini
Journal: Front Oncol Date: 2019-09-23 Impact factor: 6.244

Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much.

1. E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

Review 2. A Tumor Profile in Primary Immune Deficiencies Challenges the Cancer Immune Surveillance Concept.

Review 3. Chronic myeloid leukemia stem cells.

4. Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology.

Review 5. Prospects for achieving treatment-free remission in chronic myeloid leukaemia.

6. Will immune therapy cure acute myeloid leukemia?

7. Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib.